Page 44, please delete all of Table 7a and insert therefor the attached substitute Table 7a.

Page 45, please delete all of Table 7b and insert therefor the attached substitute Table 7b.

IN THE CLAIMS:

Please amend the claims as indicated below. A marked-up copy of the claims is attached.

3. Nucleic acid according to Claim 1, which furthermore comprises a CDR2 region, selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

D I S Y S G S T K Y K P S L R S, (SEQ ID NO:35)

(b) a nucleotide sequence which encodes the amino acid sequence:

V I S Y D G S N K Y Y A D S V K G, (SEQ ID NO:36)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

6. Nucleic acid according to Claim 4, which furthermore comprises a CDR2 region selected from:

(a) a nucleotide sequence which encodes the amino acid sequence:

G S H Q R P S, (SEQ ID NO:41)

(b) a nucleotide sequence which encodes the amino acid sequence:

S N N Q R P S, (SEQ ID NO:42)

and

(c) a nucleotide sequence which encodes an amino acid sequence having an homology of at least 80% with an amino acid sequence from (a) or (b).

B6

11. Vector, characterized in that it

(a) contains at least one copy of a nucleic acid according to Claim 1 and/or at least one copy of a nucleic acid according to Claim 4 or

(b) contains at least one copy of a nucleic acid according to Claim 7 and/or at least one copy of a nucleic acid according to Claim 9.

B7

12. Cell, characterized in that it

(a) expresses a nucleic acid according to Claim 1 and/or a nucleic acid according to Claim 4 or

(b) a nucleic acid according to Claim 7 and/or a nucleic acid according to Claim 9.

13. Polypeptide, characterized in that it

(a) is encoded by a nucleic acid according to Claim 1 and/or a nucleic acid according to Claim 4 or

(b) by a nucleic acid according to Claim 7 and/or a nucleic acid according to Claim 9.

16. Polypeptide according to Claim 13, characterized in that it is coupled to a labelling group or a toxin.

17. Antibody against a polypeptide according to Claim 13.

19. Pharmaceutical composition which comprises, as the active component, a nucleic acid according to Claim 1, a vector according to Claim 11, a cell according to Claim 12, a polypeptide according to Claim 13 or an antibody according to Claim 17, where appropriate together with other active components and pharmaceutically customary adjuvants, additives or excipients.

20. Use of a nucleic acid according to Claim 1, of a vector according to Claim 11, of a cell according to Claim 12, of a polypeptide according to Claim 13, of an antibody according to Claim 17, or of a pharmaceutical composition according to Claim 19 for preparing an agent for the diagnosis or for the treatment or prevention of AITP.